FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered “undruggable.” The company’s cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP’s to access and engage proteins that have long been known to pl...

Fang Wang
VP, Biology
Howard Stern
Martin Tremblay
VP, Chemistry
Nancy Wilker
VP, Lead IP Counsel
Sandra Smith
VP, Head of People
Stephen Fair
VP, Finance
Tony Gibney
CFO and Chief Business Officer
Weiqing Zhou

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.